Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 13,500 shares at $6.59 ($90K) on 2014-07-16, disclosed to the SEC on 2014-07-18.
Scheduled sale ($90k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.59 | 3,500 | $23K | 25.6% |
| 2 | $6.58 | 5,000 | $33K | 36.6% |
| 3 | $6.80 | 5,000 | $34K | 37.8% |
| Total | $6.66 avg | 13,500 | $90K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |